Information  X 
Enter a valid email address

Clinigen MA programme with United Therapeutics

By BFN News | 07:50 AM | Wednesday 04 November, 2015

Clinigen Group's Idis Managed Access division and United Therapeutics Corporation, a biotechnology company focused on the development and commercialisation of products for chronic and life-threatening conditions, have initiated a managed access programme for UNITUXIN (dinutuximab) injection. The programme, which will be managed by Idis MA, will enable individual adolescents and children as young as 12 months old with high risk neuroblastoma to receive UNITUXIN�?¢ (dinutuximab) injection in specific countries where the drug has not yet been commercialised. Neuroblastoma is the most common extracranial solid cancer in childhood and has the highest incidence in infancy, with approximately 1,500 patients in the European Union diagnosed each year, of whom 50% are classed as high risk. Story provided by

a d v e r t i s e m e n t